Cluster  ||| S:0 E:8 ||| NN
of  ||| S:8 E:11 ||| IN
cardiometabolic  ||| S:11 E:27 ||| JJ
risk  ||| S:27 E:32 ||| NN
factors  ||| S:32 E:40 ||| NNS
in  ||| S:40 E:43 ||| IN
children  ||| S:43 E:52 ||| NNS
with  ||| S:52 E:57 ||| IN
GH  ||| S:57 E:60 ||| NNP
deficiency ||| S:60 E:70 ||| NN
:  ||| S:70 E:72 ||| :
a  ||| S:72 E:74 ||| DT
prospective ||| S:74 E:85 ||| JJ
,  ||| S:85 E:87 ||| ,
case-control  ||| S:87 E:100 ||| JJ
study  ||| S:100 E:106 ||| NN
Growth  ||| S:106 E:113 ||| NN
hormone  ||| S:113 E:121 ||| NN
( ||| S:121 E:122 ||| -LRB-
GH ||| S:122 E:124 ||| NNP
)  ||| S:124 E:126 ||| -RRB-
deficiency  ||| S:126 E:137 ||| NN
( ||| S:137 E:138 ||| -LRB-
GHD ||| S:138 E:141 ||| NNP
)  ||| S:141 E:143 ||| -RRB-
in  ||| S:143 E:146 ||| IN
adults  ||| S:146 E:153 ||| NNS
is  ||| S:153 E:156 ||| VBZ
associated  ||| S:156 E:167 ||| VBN
with  ||| S:167 E:172 ||| IN
increased  ||| S:172 E:182 ||| JJ
cardiovascular  ||| S:182 E:197 ||| NNS
( ||| S:197 E:198 ||| -LRB-
CV ||| S:198 E:200 ||| NNP
)  ||| S:200 E:202 ||| -RRB-
risk ||| S:202 E:206 ||| NN
.  ||| S:206 E:208 ||| .
Although  ||| S:208 E:217 ||| IN
some  ||| S:217 E:222 ||| DT
authors  ||| S:222 E:230 ||| NNS
have  ||| S:230 E:235 ||| VBP
documented  ||| S:235 E:246 ||| VBN
the  ||| S:246 E:250 ||| DT
presence  ||| S:250 E:259 ||| NN
of  ||| S:259 E:262 ||| IN
early  ||| S:262 E:268 ||| JJ
CV  ||| S:268 E:271 ||| NNP
risk  ||| S:271 E:276 ||| NN
factors  ||| S:276 E:284 ||| NNS
in  ||| S:284 E:287 ||| IN
untreated  ||| S:287 E:297 ||| JJ
GHD  ||| S:297 E:301 ||| NN
children ||| S:301 E:309 ||| NNS
,  ||| S:309 E:311 ||| ,
results  ||| S:311 E:319 ||| NNS
are  ||| S:319 E:323 ||| VBP
still  ||| S:323 E:329 ||| RB
inconsistent ||| S:329 E:341 ||| JJ
.  ||| S:341 E:343 ||| .
Aim  ||| S:343 E:347 ||| NN
of  ||| S:347 E:350 ||| IN
this  ||| S:350 E:355 ||| DT
study  ||| S:355 E:361 ||| NN
was  ||| S:361 E:365 ||| VBD
to  ||| S:365 E:368 ||| TO
evaluate  ||| S:368 E:377 ||| VB
the  ||| S:377 E:381 ||| DT
effects  ||| S:381 E:389 ||| NNS
of  ||| S:389 E:392 ||| IN
GHD  ||| S:392 E:396 ||| NNP
and  ||| S:396 E:400 ||| CC
GH  ||| S:400 E:403 ||| NNP
therapy  ||| S:403 E:411 ||| NN
on  ||| S:411 E:414 ||| IN
early  ||| S:414 E:420 ||| JJ
cardiometabolic  ||| S:420 E:436 ||| JJ
risk  ||| S:436 E:441 ||| NN
factors  ||| S:441 E:449 ||| NNS
in  ||| S:449 E:452 ||| IN
a  ||| S:452 E:454 ||| DT
large  ||| S:454 E:460 ||| JJ
cohort  ||| S:460 E:467 ||| NN
of  ||| S:467 E:470 ||| IN
children ||| S:470 E:478 ||| NNS
.  ||| S:478 E:480 ||| .
Waist-to-height  ||| S:480 E:496 ||| JJ
ratio  ||| S:496 E:502 ||| NN
( ||| S:502 E:503 ||| -LRB-
WHtR ||| S:503 E:507 ||| NNP
) ||| S:507 E:508 ||| -RRB-
,  ||| S:508 E:510 ||| ,
triglycerides ||| S:510 E:523 ||| NN
,  ||| S:523 E:525 ||| ,
total- ||| S:525 E:531 ||| NNP
,  ||| S:531 E:533 ||| ,
low-density  ||| S:533 E:545 ||| NN
lipoprotein  ||| S:545 E:557 ||| NNS
( ||| S:557 E:558 ||| -LRB-
LDL ||| S:558 E:561 ||| NNP
) ||| S:561 E:562 ||| -RRB-
,  ||| S:562 E:564 ||| ,
high-density  ||| S:564 E:577 ||| JJ
lipoprotein  ||| S:577 E:589 ||| NNS
( ||| S:589 E:590 ||| -LRB-
HDL ||| S:590 E:593 ||| NNP
)  ||| S:593 E:595 ||| -RRB-
cholesterol ||| S:595 E:606 ||| NN
,  ||| S:606 E:608 ||| ,
atherogenic  ||| S:608 E:620 ||| JJ
index  ||| S:620 E:626 ||| NN
( ||| S:626 E:627 ||| -LRB-
AI  ||| S:627 E:630 ||| NNP
=  ||| S:630 E:632 ||| SYM
total  ||| S:632 E:638 ||| FW
/ ||| S:638 E:639 ||| FW
HDL  ||| S:639 E:643 ||| FW
cholesterol ||| S:643 E:654 ||| FW
) ||| S:654 E:655 ||| -RRB-
,  ||| S:655 E:657 ||| ,
homocysteine ||| S:657 E:669 ||| NN
,  ||| S:669 E:671 ||| ,
leptin ||| S:671 E:677 ||| NN
,  ||| S:677 E:679 ||| ,
adiponectin ||| S:679 E:690 ||| NN
,  ||| S:690 E:692 ||| ,
high-sensitivity  ||| S:692 E:709 ||| JJ
C-reactive  ||| S:709 E:720 ||| JJ
protein  ||| S:720 E:728 ||| NN
( ||| S:728 E:729 ||| -LRB-
hsCRP ||| S:729 E:734 ||| NNP
)  ||| S:734 E:736 ||| -RRB-
and  ||| S:736 E:740 ||| CC
fibrinogen  ||| S:740 E:751 ||| NNS
were  ||| S:751 E:756 ||| VBD
evaluated  ||| S:756 E:766 ||| VBN
in  ||| S:766 E:769 ||| IN
seventy-one  ||| S:769 E:781 ||| NNP
GHD  ||| S:781 E:785 ||| NNP
children  ||| S:785 E:794 ||| NNS
( ||| S:794 E:795 ||| -LRB-
9·8  ||| S:795 E:799 ||| CD
±  ||| S:799 E:801 ||| CD
3·6  ||| S:801 E:805 ||| CD
years ||| S:805 E:810 ||| NNS
)  ||| S:810 E:812 ||| -RRB-
before  ||| S:812 E:819 ||| IN
and  ||| S:819 E:823 ||| CC
after  ||| S:823 E:829 ||| IN
2  ||| S:829 E:831 ||| CD
years  ||| S:831 E:837 ||| NNS
of  ||| S:837 E:840 ||| IN
GH  ||| S:840 E:843 ||| NNP
therapy ||| S:843 E:850 ||| NN
.  ||| S:850 E:852 ||| .
Seventy-one  ||| S:852 E:864 ||| JJ
healthy  ||| S:864 E:872 ||| JJ
controls  ||| S:872 E:881 ||| NNS
comparable  ||| S:881 E:892 ||| JJ
with  ||| S:892 E:897 ||| IN
patients  ||| S:897 E:906 ||| NNS
for  ||| S:906 E:910 ||| IN
age ||| S:910 E:913 ||| NN
,  ||| S:913 E:915 ||| ,
sex  ||| S:915 E:919 ||| NN
and  ||| S:919 E:923 ||| CC
body  ||| S:923 E:928 ||| NN
mass  ||| S:928 E:933 ||| NN
index  ||| S:933 E:939 ||| NN
( ||| S:939 E:940 ||| -LRB-
BMI ||| S:940 E:943 ||| NNP
)  ||| S:943 E:945 ||| -RRB-
were  ||| S:945 E:950 ||| VBD
enrolled ||| S:950 E:958 ||| VBN
.  ||| S:958 E:960 ||| .
Compared  ||| S:960 E:969 ||| VBN
with  ||| S:969 E:974 ||| IN
controls ||| S:974 E:982 ||| NNS
,  ||| S:982 E:984 ||| ,
GHD  ||| S:984 E:988 ||| NNP
children  ||| S:988 E:997 ||| NNS
at  ||| S:997 E:1000 ||| IN
study  ||| S:1000 E:1006 ||| NN
entry  ||| S:1006 E:1012 ||| NN
had  ||| S:1012 E:1016 ||| VBD
higher  ||| S:1016 E:1023 ||| JJR
WHtR  ||| S:1023 E:1028 ||| NNS
( ||| S:1028 E:1029 ||| -LRB-
0·52  ||| S:1029 E:1034 ||| FW
±  ||| S:1034 E:1036 ||| FW
0·05  ||| S:1036 E:1041 ||| FW
vs  ||| S:1041 E:1044 ||| FW
0·45  ||| S:1044 E:1049 ||| FW
±  ||| S:1049 E:1051 ||| FW
0·19 ||| S:1051 E:1055 ||| FW
,  ||| S:1055 E:1057 ||| ,
P  ||| S:1057 E:1059 ||| NN
=  ||| S:1059 E:1061 ||| SYM
0·004 ||| S:1061 E:1066 ||| CD
) ||| S:1066 E:1067 ||| -RRB-
,  ||| S:1067 E:1069 ||| ,
triglycerides  ||| S:1069 E:1083 ||| NNS
( ||| S:1083 E:1084 ||| -LRB-
0·44  ||| S:1084 E:1089 ||| FW
±  ||| S:1089 E:1091 ||| FW
0·98  ||| S:1091 E:1096 ||| FW
vs  ||| S:1096 E:1099 ||| FW
-0·03  ||| S:1099 E:1105 ||| FW
±  ||| S:1105 E:1107 ||| FW
0·73  ||| S:1107 E:1112 ||| FW
SDS ||| S:1112 E:1115 ||| NNP
,  ||| S:1115 E:1117 ||| ,
P  ||| S:1117 E:1119 ||| NN
=  ||| S:1119 E:1121 ||| SYM
0·012 ||| S:1121 E:1126 ||| CD
) ||| S:1126 E:1127 ||| -RRB-
,  ||| S:1127 E:1129 ||| ,
total  ||| S:1129 E:1135 ||| JJ
cholesterol  ||| S:1135 E:1147 ||| NN
( ||| S:1147 E:1148 ||| -LRB-
0·28  ||| S:1148 E:1153 ||| FW
±  ||| S:1153 E:1155 ||| FW
1·08  ||| S:1155 E:1160 ||| FW
vs  ||| S:1160 E:1163 ||| FW
-0·46  ||| S:1163 E:1169 ||| FW
±  ||| S:1169 E:1171 ||| FW
0·98  ||| S:1171 E:1176 ||| FW
SDS ||| S:1176 E:1179 ||| NNP
,  ||| S:1179 E:1181 ||| ,
P  ||| S:1181 E:1183 ||| NNP
< ||| S:1183 E:1185 ||| SYM
0·001 ||| S:1185 E:1190 ||| NNP
) ||| S:1190 E:1191 ||| -RRB-
,  ||| S:1191 E:1193 ||| ,
LDL  ||| S:1193 E:1197 ||| NNP
cholesterol  ||| S:1197 E:1209 ||| NN
( ||| S:1209 E:1210 ||| -LRB-
0·20  ||| S:1210 E:1215 ||| FW
±  ||| S:1215 E:1217 ||| FW
0·90  ||| S:1217 E:1222 ||| FW
vs  ||| S:1222 E:1225 ||| FW
-0·39  ||| S:1225 E:1231 ||| FW
±  ||| S:1231 E:1233 ||| FW
1·06  ||| S:1233 E:1238 ||| FW
SDS ||| S:1238 E:1241 ||| NNP
,  ||| S:1241 E:1243 ||| ,
P  ||| S:1243 E:1245 ||| NN
=  ||| S:1245 E:1247 ||| SYM
0·007 ||| S:1247 E:1252 ||| CD
) ||| S:1252 E:1253 ||| -RRB-
,  ||| S:1253 E:1255 ||| ,
AI  ||| S:1255 E:1258 ||| NNP
( ||| S:1258 E:1259 ||| -LRB-
3·19  ||| S:1259 E:1264 ||| FW
±  ||| S:1264 E:1266 ||| FW
0·73  ||| S:1266 E:1271 ||| FW
vs  ||| S:1271 E:1274 ||| FW
2·77  ||| S:1274 E:1279 ||| FW
±  ||| S:1279 E:1281 ||| FW
0·53 ||| S:1281 E:1285 ||| FW
,  ||| S:1285 E:1287 ||| ,
P  ||| S:1287 E:1289 ||| NN
=  ||| S:1289 E:1291 ||| SYM
0·001 ||| S:1291 E:1296 ||| CD
) ||| S:1296 E:1297 ||| -RRB-
,  ||| S:1297 E:1299 ||| ,
homocysteine  ||| S:1299 E:1312 ||| NNS
( ||| S:1312 E:1313 ||| -LRB-
8·45  ||| S:1313 E:1318 ||| FW
±  ||| S:1318 E:1320 ||| FW
1·8  ||| S:1320 E:1324 ||| FW
vs  ||| S:1324 E:1327 ||| FW
7·72  ||| S:1327 E:1332 ||| FW
±  ||| S:1332 E:1334 ||| FW
1·6  ||| S:1334 E:1338 ||| FW
μm ||| S:1338 E:1340 ||| FW
,  ||| S:1340 E:1342 ||| ,
P  ||| S:1342 E:1344 ||| NN
=  ||| S:1344 E:1346 ||| SYM
0·003 ||| S:1346 E:1351 ||| CD
) ||| S:1351 E:1352 ||| -RRB-
,  ||| S:1352 E:1354 ||| ,
leptin  ||| S:1354 E:1361 ||| NNS
( ||| S:1361 E:1362 ||| -LRB-
8·03  ||| S:1362 E:1367 ||| FW
±  ||| S:1367 E:1369 ||| FW
4·2  ||| S:1369 E:1373 ||| FW
vs  ||| S:1373 E:1376 ||| FW
5·09  ||| S:1376 E:1381 ||| FW
±  ||| S:1381 E:1383 ||| FW
1·9  ||| S:1383 E:1387 ||| FW
ng ||| S:1387 E:1389 ||| FW
/ ||| S:1389 E:1390 ||| FW
ml ||| S:1390 E:1392 ||| FW
,  ||| S:1392 E:1394 ||| ,
P  ||| S:1394 E:1396 ||| NN
=  ||| S:1396 E:1398 ||| SYM
0·001 ||| S:1398 E:1403 ||| CD
)  ||| S:1403 E:1405 ||| -RRB-
and  ||| S:1405 E:1409 ||| CC
fibrinogen  ||| S:1409 E:1420 ||| NNS
( ||| S:1420 E:1421 ||| -LRB-
292·6  ||| S:1421 E:1427 ||| CD
±  ||| S:1427 E:1429 ||| CD
33  ||| S:1429 E:1432 ||| CD
vs  ||| S:1432 E:1435 ||| CD
268  ||| S:1435 E:1439 ||| CD
±  ||| S:1439 E:1441 ||| CD
31·4  ||| S:1441 E:1446 ||| CD
mg ||| S:1446 E:1448 ||| CD
/ ||| S:1448 E:1449 ||| CD
dl ||| S:1449 E:1451 ||| NN
,  ||| S:1451 E:1453 ||| ,
P  ||| S:1453 E:1455 ||| NN
=  ||| S:1455 E:1457 ||| SYM
0·011 ||| S:1457 E:1462 ||| CD
) ||| S:1462 E:1463 ||| -RRB-
.  ||| S:1463 E:1465 ||| .
No  ||| S:1465 E:1468 ||| DT
differences  ||| S:1468 E:1480 ||| NNS
were  ||| S:1480 E:1485 ||| VBD
found  ||| S:1485 E:1491 ||| VBN
in  ||| S:1491 E:1494 ||| IN
adiponectin  ||| S:1494 E:1506 ||| NN
or  ||| S:1506 E:1509 ||| CC
hsCRP ||| S:1509 E:1514 ||| JJ
.  ||| S:1514 E:1516 ||| .
GH  ||| S:1516 E:1519 ||| NNP
therapy  ||| S:1519 E:1527 ||| NN
was  ||| S:1527 E:1531 ||| VBD
associated  ||| S:1531 E:1542 ||| VBN
with  ||| S:1542 E:1547 ||| IN
a  ||| S:1547 E:1549 ||| DT
significant  ||| S:1549 E:1561 ||| JJ
reduction  ||| S:1561 E:1571 ||| NN
in  ||| S:1571 E:1574 ||| IN
WHtR  ||| S:1574 E:1579 ||| NNP
( ||| S:1579 E:1580 ||| -LRB-
P  ||| S:1580 E:1582 ||| NNP
< ||| S:1582 E:1584 ||| SYM
0·001 ||| S:1584 E:1589 ||| NNP
) ||| S:1589 E:1590 ||| -RRB-
,  ||| S:1590 E:1592 ||| ,
total  ||| S:1592 E:1598 ||| JJ
cholesterol  ||| S:1598 E:1610 ||| NN
( ||| S:1610 E:1611 ||| -LRB-
P  ||| S:1611 E:1613 ||| NNP
< ||| S:1613 E:1615 ||| SYM
0·001 ||| S:1615 E:1620 ||| NNP
) ||| S:1620 E:1621 ||| -RRB-
,  ||| S:1621 E:1623 ||| ,
LDL  ||| S:1623 E:1627 ||| NNP
cholesterol  ||| S:1627 E:1639 ||| NN
( ||| S:1639 E:1640 ||| -LRB-
P  ||| S:1640 E:1642 ||| NN
=  ||| S:1642 E:1644 ||| SYM
0·002 ||| S:1644 E:1649 ||| CD
) ||| S:1649 E:1650 ||| -RRB-
,  ||| S:1650 E:1652 ||| ,
homocysteine  ||| S:1652 E:1665 ||| NNS
( ||| S:1665 E:1666 ||| -LRB-
P  ||| S:1666 E:1668 ||| NN
=  ||| S:1668 E:1670 ||| SYM
0·044 ||| S:1670 E:1675 ||| CD
)  ||| S:1675 E:1677 ||| -RRB-
leptin  ||| S:1677 E:1684 ||| NNS
( ||| S:1684 E:1685 ||| -LRB-
P  ||| S:1685 E:1687 ||| NN
=  ||| S:1687 E:1689 ||| SYM
0·022 ||| S:1689 E:1694 ||| CD
)  ||| S:1694 E:1696 ||| -RRB-
and  ||| S:1696 E:1700 ||| CC
fibrinogen  ||| S:1700 E:1711 ||| NNS
( ||| S:1711 E:1712 ||| -LRB-
P  ||| S:1712 E:1714 ||| NN
=  ||| S:1714 E:1716 ||| SYM
0·001 ||| S:1716 E:1721 ||| CD
) ||| S:1721 E:1722 ||| -RRB-
.  ||| S:1722 E:1724 ||| .
Moreover ||| S:1724 E:1732 ||| RB
,  ||| S:1732 E:1734 ||| ,
GH  ||| S:1734 E:1737 ||| NNP
therapy  ||| S:1737 E:1745 ||| NN
was  ||| S:1745 E:1749 ||| VBD
associated  ||| S:1749 E:1760 ||| VBN
with  ||| S:1760 E:1765 ||| IN
a  ||| S:1765 E:1767 ||| DT
significant  ||| S:1767 E:1779 ||| JJ
increase  ||| S:1779 E:1788 ||| NN
in  ||| S:1788 E:1791 ||| IN
adiponectin  ||| S:1791 E:1803 ||| JJ
levels  ||| S:1803 E:1810 ||| NNS
( ||| S:1810 E:1811 ||| -LRB-
P  ||| S:1811 E:1813 ||| NN
=  ||| S:1813 E:1815 ||| SYM
0·001 ||| S:1815 E:1820 ||| CD
) ||| S:1820 E:1821 ||| -RRB-
.  ||| S:1821 E:1823 ||| .
Our  ||| S:1823 E:1827 ||| PRP$
data  ||| S:1827 E:1832 ||| NNS
suggest  ||| S:1832 E:1840 ||| VBP
that  ||| S:1840 E:1845 ||| IN
children  ||| S:1845 E:1854 ||| NNS
with  ||| S:1854 E:1859 ||| IN
untreated  ||| S:1859 E:1869 ||| JJ
GHD  ||| S:1869 E:1873 ||| NNP
exhibit  ||| S:1873 E:1881 ||| VBD
a  ||| S:1881 E:1883 ||| DT
cluster  ||| S:1883 E:1891 ||| NN
of  ||| S:1891 E:1894 ||| IN
early  ||| S:1894 E:1900 ||| JJ
cardiovascular  ||| S:1900 E:1915 ||| JJ
risk  ||| S:1915 E:1920 ||| NN
factors  ||| S:1920 E:1928 ||| NNS
and  ||| S:1928 E:1932 ||| CC
that  ||| S:1932 E:1937 ||| IN
GH  ||| S:1937 E:1940 ||| NNP
treatment  ||| S:1940 E:1950 ||| NN
exerts  ||| S:1950 E:1957 ||| VBZ
beneficial  ||| S:1957 E:1968 ||| JJ
effects  ||| S:1968 E:1976 ||| NNS
on  ||| S:1976 E:1979 ||| IN
these  ||| S:1979 E:1985 ||| DT
abnormalities ||| S:1985 E:1998 ||| NN
.  ||| S:1998 E:2000 ||| .
